Incyte Corporation (INCY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. In the interest of time, we ask that you please limit yourselves to one question, then return to the queue. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Greg Scherzer, Investor Relations. Please go ahead, Greg. Thank you, Kevin. Good morning, and welcome to Insight's first quarter 2025 earnings conference call. Before we begin, I encourage everyone to go to the Investor section of our website to find the press release, related financial tables, and slides that follow today's discussion. On today's call, I'm joined by Irvay. Pablo, and Christiana, who will deliver our prepared remarks. Mateo, Mohamed, and Steven will also be available for the Q&A. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. I'll now hand the call over to Hervé. Thank you, Greg, and good morning, everyone. The first quarter of 25 was very important for Insight, not only because of the good performance of the commercial portfolio, but mostly because Q1 25 puts us on a great trajectory for long-term growth with the continuous expansion of Opsedura, the successful launch of Nick Thimble, and the successes of the pivotal studies in HS and proof-of-concept ...